Page 7,149«..1020..7,1487,1497,1507,151..7,1607,170..»

Everist Genomics Celebrates Origins and Future of Personalized Medicine

Posted: Published on February 13th, 2012

ANN ARBOR, Mich., Feb. 13, 2012 /PRNewswire/ -- Everist Genomics, a rapidly growing personalized medicine company, today announced that world-renowned scientist and genome sequencing pioneer Dr. J. Craig Venter will be the keynote speaker for its March 26th Gala Dinner at the Field Museum in Chicago.   (Photo:  http://photos.prnewswire.com/prnh/20120213/NY52008&nbspšŸ˜‰ (Logo:  http://photos.prnewswire.com/prnh/20110110/NY26865LOGO&nbspšŸ˜‰ Dr. Venter achieved global prominence in 2001 for being the first to sequence the human genome, accomplishing this feat two years in advance of the government-sponsored Human Genome Project and at a fraction of the cost. He received acclaim again in 2010 for leading a team of scientists to create the first synthetic life form, a single-cell bacterium known as Mycoplasma laboratorium. His contributions to the field of genomics—including the decoding of his own genome—have enabled the new era of personalized medicine, in which treatment of medical conditions are tailored to individual patients. Dr. Venter, who was twice named to Time magazine's list of the world's 100 most influential people, founded the J. Craig Venter Institute, a research organization with more than 500 scientists and staff dedicated to human, microbial, plant, synthetic and environmental genomic research and the exploration of social and ethical issues in genomics. Dr. Venter is also … Continue reading

Posted in Cell Medicine | Comments Off on Everist Genomics Celebrates Origins and Future of Personalized Medicine

Foundation Medicine and Dana-Farber Cancer Institute Identify Novel Genomic Alterations in Lung and Colorectal Cancer

Posted: Published on February 13th, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer gene analysis to routine clinical care, and Dana-Farber Cancer Institute today announced the Nature Medicine publication of results from their collaborative next-generation sequencing (NGS) study to assay cancer-relevant genes in 24 non-small cell lung cancer (NSCLC) and 40 colorectal cancer (CRC) cases. In this study, 59% of the samples were found to have genomic alterations directly associated with a clinically-available targeted therapeutic or a relevant clinical trial of a targeted therapy. Two novel gene fusions, KIF5B-RET in NSCLC and C2orf44-ALK in CRC, were discovered among the potentially druggable alterations identified in the study. Both of these findings may expand therapeutic options for a subset of cancer patients. This publication demonstrates that using targeted NGS to profile patient tumors for molecular alterations associated with therapeutic responses may have an important clinical impact in cancer treatment. ā€œIn this collaboration, we detected clinically-relevant genomic alterations in more than half of the samples profiled, and, because Foundation Medicine’s NGS assay detects all classes of alterations with clinical-grade sensitivity, this research was able to identify both expected as well as completely novel alterations,ā€ said Maureen Cronin, Ph.D., senior vice president, research … Continue reading

Posted in Cell Medicine | Comments Off on Foundation Medicine and Dana-Farber Cancer Institute Identify Novel Genomic Alterations in Lung and Colorectal Cancer

The Gamida Cell-Teva Joint Venture Concludes Enrollment for the Phase III Study of StemExĀ®, a Cord Blood Stem Cell …

Posted: Published on February 13th, 2012

JERUSALEM--(BUSINESS WIRE)-- Gamida Cell announced today that the Gamida Cell-Teva Joint Venture (JV), equally held by Gamida Cell and Teva Pharmaceutical Industries, has enrolled the last of 100 patients in the international, multi-center, pivotal registration, Phase III clinical trial of StemEx, a cell therapy product in development as an alternative therapeutic treatment for adolescents and adults, with blood cancers such as leukemia and lymphoma, who cannot find a family related, matched bone marrow donor. StemEx is a graft of an expanded population of stem/progenitor cells, derived from part of a single unit of umbilical cord blood and transplanted by IV administration along with the remaining, non-manipulated cells from the same unit. Dr. Yael Margolin, president and chief executive officer of Gamida Cell, said, "The JV is planning to announce the safety and efficacy results of the Phase III StemEx trial in 2012 and to launch the product into the market in 2013. It is our hope that StemEx will provide the answer for the thousands of leukemia and lymphoma patients unable to find a matched, related bone marrow donor.ā€ Dr. Margolin continued, ā€œStemEx may be the first allogeneic cell therapy to be brought to market. This is a source of … Continue reading

Posted in Cell Therapy | Comments Off on The Gamida Cell-Teva Joint Venture Concludes Enrollment for the Phase III Study of StemExĀ®, a Cord Blood Stem Cell …

Catalyst Pharm updates EC stance on CPP-115

Posted: Published on February 13th, 2012

Catalyst Pharmaceutical Partners announced that the European Commission, EC, has granted orphan medicinal product designation for the company's investigational drug, CPP-115, a novel GABA aminotransferase inhibitor, for the treatment of West Syndrome (infantile spasms). The EC designation is based on the recommendation by the European Medicines Agency (EMA) Committee on Orphan Medicinal Products (COMP) after their review of all relevant preclinical data for CPP-115, which showed that it may have a longer duration of action, improved benefits and fewer retinal side effects than the existing first-line treatment. "We have hit another major milestone in our efforts to advance this clinically important treatment for patients around the world," said Patrick J. McEnany, Chief Executive Officer of Catalyst. "Obtaining an orphan designation for CPP-115 in the European Union (EU) is an important step that builds upon our recent progress with CPP-115, including the grant of Fast Track development program designation by the U.S. Food and Drug Administration (FDA) for cocaine dependency and commencement of a first-in-man Phase I(a) safety study." See the original post: Catalyst Pharm updates EC stance on CPP-115 … Continue reading

Posted in Drug Dependency | Comments Off on Catalyst Pharm updates EC stance on CPP-115

Catalyst Pharma's Infantile Spasms Therapy CPP-115 Gets EC Orphan Drug Status

Posted: Published on February 13th, 2012

(RTTNews.com) - Catalyst Pharmaceuticals Partners Inc. (CPRX) Monday reported that its West Syndrome, or infantile spasms, therapy CPP-115 was given orphan medicinal product designation by the European Commission upon the recommendation of the European Medicines Agency, or EMA, Committee on Orphan Medicinal Products, or COMP. The decision was based on preclinical data which showed CPP-115 as being active for a longer time, and resulting in fewer retinal side effects. Patrick McEnany, Catalyst's chief executive officer, said "We have hit another major milestone in our efforts to advance this clinically important treatment for patients around the world. Obtaining an orphan designation for CPP-115 in the European Union (EU) is an important step that builds upon our recent progress with CPP-115, including the grant of Fast Track development program designation by the U.S. Food and Drug Administration (FDA) for cocaine dependency and commencement of a first-in-man Phase I(a) safety study." For comments and feedback: contact editorial@rttnews.com http://www.rttnews.com More here: Catalyst Pharma's Infantile Spasms Therapy CPP-115 Gets EC Orphan Drug Status … Continue reading

Posted in Drug Dependency | Comments Off on Catalyst Pharma's Infantile Spasms Therapy CPP-115 Gets EC Orphan Drug Status

Catalyst Pharmaceutical Partners Granted Orphan Medicinal Product Designation in European Union for CPP-115 for the …

Posted: Published on February 13th, 2012

CORAL GABLES, Fla., Feb. 13, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX - News) today announced that the European Commission (EC) has granted orphan medicinal product designation for the company's investigational drug, CPP-115, a novel GABA aminotransferase inhibitor, for the treatment of West Syndrome (infantile spasms). The EC designation is based on the recommendation by the European Medicines Agency (EMA) Committee on Orphan Medicinal Products (COMP) after their review of all relevant preclinical data for CPP-115, which showed that it may have a longer duration of action, improved benefits and fewer retinal side effects than the existing first-line treatment. "We have hit another major milestone in our efforts to advance this clinically important treatment for patients around the world," said Patrick J. McEnany, Chief Executive Officer of Catalyst. "Obtaining an orphan designation for CPP-115 in the European Union (EU) is an important step that builds upon our recent progress with CPP-115, including the grant of Fast Track development program designation by the U.S. Food and Drug Administration (FDA) for cocaine dependency and commencement of a first-in-man Phase I(a) safety study." "Our orphan designations in the EU and U.S. support our global development strategy for CPP-115 and our goal … Continue reading

Posted in Drug Dependency | Comments Off on Catalyst Pharmaceutical Partners Granted Orphan Medicinal Product Designation in European Union for CPP-115 for the …

Celine Dion: "Drugs" and "Show Business" Killed Whitney Houston

Posted: Published on February 13th, 2012

The cause of Whitney Houston's death remains under investigation -- but according to Celine Dion, this case is already closed. Speaking via phone on Monday's Good Morning America (she called the late icon "an amazing inspiration") the "My Heart Will Go On" singer didn't mince words looking back on Houston's legendary career and troubled later life. PHOTOS: Whitney's life remembered "It's just really unfortunate that drugs, bad people, bad influences took over her dreams, her motherhood," the French-Canadian star, 43, said of Houston, who famously fessed up in a 2002 interview with Diane Sawyer about using cocaine, marijuana and pills. "When you think about Elvis Presley, Marilyn Monroe, Amy Winehouse, Michael Jackson . . . To get into drugs like that for whatever reason--because of stress, bad influence, whatever." PHOTOS: Tragic celeb deaths of 2011 Dion lamented that her immensely talented idol, who left behind daughter Bobbi Kristina, apparently succumbed like other superstars before her. "What happens when you have everything? Love, support, motherhood…Something happens that I don't understand. That's why I'm scared of show business, of drugs and hanging out. That's why I don't go to parties!" PHOTOS: The troubled life of Amy Winehouse Tell Us: Did Dion speak … Continue reading

Posted in Drugs | Comments Off on Celine Dion: "Drugs" and "Show Business" Killed Whitney Houston

Proteins hope for cancer drugs

Posted: Published on February 13th, 2012

13 February 2012 Last updated at 09:55 ET New insights into how cells multiply could help scientists develop drugs to treat cancer, it has been claimed. Edinburgh University researchers have been studying two key proteins which control cell division. They have found a link between the proteins' activity and formation of new healthy cells, which could be vital to the development of anti-cancer drugs. The team from Edinburgh is working in collaboration with researchers at Montreal University in Canada. They have identified a key process in the way the proteins called "polo" and "aurora" work to divide cells correctly. Their discovery will contribute to the development of new drugs which stop cancerous cells multiplying and so prevent the spread of the disease. Dr Mar Carmena, of Edinburgh University's school of biological sciences, said: "Cell division is a complex and tightly regulated process, and when it goes out of control this can lead to cancer. "The greater our understanding of the proteins that control cell division, the better equipped scientists will be to design more effective treatments against cancer." More: Proteins hope for cancer drugs … Continue reading

Posted in Drugs | Comments Off on Proteins hope for cancer drugs

Legalizing drugs gains ground in Latin America

Posted: Published on February 13th, 2012

Guatemalan President Otto Perez Molina has suggested decriminalizing drugs in order to reduce violence in the Americas. • A version of this post ran on the author's blog, centralamericanpolitics.blogspot.com. The views expressed are the author's own. Skip to next paragraph Guatemalan President Otto Perez Molina has repeated his suggestion that Guatemala and the other nations of Central America should consider decriminalizing drugs in order to help reduce violence. The Guatemalan president said he will propose legalizing drugs in Central America in an upcoming meeting with the region's leaders. President Perez Molina said in a radio interview that legalization would include decriminalizing the transportation of drugs through the area. The Guatemalan president said the war on drugs, and all the money and technology received from the US, has not diminished drug trafficking in the area. While the details would have to be worked out, he would also consider setting up legal mechanisms to sell drugs (link in Spanish). Some effort at decriminalization would be beneficial both to the people of Central America and the United States. On the other hand, I'm not convinced that the US government and regional governments could design some sort of effective policy. They would include too … Continue reading

Posted in Drugs | Comments Off on Legalizing drugs gains ground in Latin America

Online Clinical Education Platform Pedagogy Gains in Popularity

Posted: Published on February 13th, 2012

Husband and Wife Team Up to Develop Successful Formula for Delivering Valuable Courses to Health Care Professionals Tyler, TX (PRWEB) February 13, 2012 Realizing the need for an efficient and effective means to provide educational and training courses for nurses, nurse practitioners, physicians, pharmacists, nurse aids and medical assistants, Patrick and Capra Dalton decided to apply their respective skills to create Pedagogy, Inc. As a consultant for a national pharmacy company serving long term care facilities, Capra Dalton, RN and Pedagogy CEO, previously traveled throughout the state of Texas teaching infusion therapy to nurses within a traditional classroom setting. ā€œI began to notice that nurses were having difficulty travelling to locations for these two-day courses due to conflicts with their typical work schedules, child care issues, travel expenses, and of course, ensuring proper coverage at the nursing homes where they worked,ā€ observed Capra. Relaying her experiences to her husband, Patrick Dalton, Capra was at first skeptical about Patrick’s suggestion that the courses could be delivered online. However the more Capra thought about Patrick’s idea, the more the it took hold, ā€œI realized that these classes could be presented in an online format and resolve so many barriers that traditional classroom … Continue reading

Posted in Online Pharmacy | Comments Off on Online Clinical Education Platform Pedagogy Gains in Popularity

Page 7,149«..1020..7,1487,1497,1507,151..7,1607,170..»